ATHE - ALTERITY THERAPEUTICS LTD

3.62
0.070   1.934%

Share volume: 9,842
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$3.55
0.07
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
31%
Profitability 0%
Dept financing 18%
Liquidity 50%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.54%
1 Month
2.55%
3 Months
5.85%
6 Months
-26.69%
1 Year
-3.72%
2 Year
111.70%
Key data
Stock price
$3.62
P/E Ratio 
0.00
DAY RANGE
$3.48 - $3.63
EPS 
N/A
52 WEEK RANGE
$2.52 - $7.00
52 WEEK CHANGE
-$5.48
MARKET CAP 
73.604 M
YIELD 
N/A
SHARES OUTSTANDING 
8.867 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$12,719
AVERAGE 30 VOLUME 
$10,084
Company detail
CEO: David A. Stamler
Region: US
Website: alteritytherapeutics.com
Employees: 10
IPO year: 2003
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's Disease.

Recent news